Sign up
Pharma Capital

Summit Therapeutics soars as it hails potential of very early stage antibiotic

The treatment has been developed to tackle a gram-negative bacteria that is becoming resistant to current drugs
research inspecting petri dish
The data were presented at the European Congress of Clinical Microbiology & Infectious Diseases, taking place in Amsterdam

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) shares soared higher on Monday as the firm trumpeted the early success of a pre-clinical antibiotic that may help overcome drug resistance to a potentially deadly infection.

The group said it presented data at a leading healthcare conference that showed its treatment, DDS-04, had successfully tackled bacteria called Enterobacteriaceae in animals with urinary tract infections.

Resistant strain

Antimicrobial resistance means people contracting the gram-negative bacterial strain, which also affects the lungs and bloodstream, “are increasingly at risk for poor outcomes”, said Dr David Roblin, Summit’s head of research and development.

“Mainstay treatments are losing their effectiveness, and patients do not have the luxury of time to fail antibiotic therapy,” he explained. “There is a pressing need for new, targeted Enterobacteriaceae antibiotics that can serve to improve patient outcomes.”

The data were presented at the European Congress of Clinical Microbiology & Infectious Diseases, taking place in Amsterdam.

In early afternoon trading in London, Summit shares were 17.3% higher at 32.25p.

 -- Adds share price --

Ian_55ae0ddd437b7.jpg
Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.